Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RGH 2716

Drug Profile

RGH 2716

Alternative Names: TDN 345

Latest Information Update: 11 Oct 2000

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takeda
  • Developer Gedeon Richter
  • Class Anti-ischaemics; Neuroprotectants; Nootropics
  • Mechanism of Action Calcium channel antagonists; Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cerebral ischaemia; Cognition disorders

Most Recent Events

  • 11 Oct 2000 Discontinued-Preclinical for Cerebral ischaemia in Hungary (Unknown route)
  • 11 Oct 2000 Discontinued-Preclinical for Cognition disorders in Hungary (Unknown route)
  • 12 Jun 2000 Profile reviewed but no significant changes made
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top